Sungen Biomedical
Daxing
About Sungen Biomedical
Sungen Biomedical is engaged in the development of first-in-class (FIC) antibody therapeutics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $41.7M
- Funding stage: Early Stage Venture
- Last round: Series A (May 2025)
- Website: sungenbiomed.com
- Phone: +86 01050986588
Industries & Categories
Biopharma, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/sungen-biomedical-9812 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.